Core Insights - TNX-4800 is a long-acting monoclonal antibody in development as a single-dose prophylactic for Lyme disease, demonstrating safety and pharmacokinetics supportive of approximately four months of protection [1][2][3] Phase 1 Study Results - The Phase 1 study evaluated the safety and tolerability of TNX-4800 in 44 healthy subjects aged 19-65, with 41 completing the study [4][10] - No significant safety signals were observed, with most adverse events being mild or moderate [5][12] - Peak serum concentration increased by approximately 25-fold for a 20-times increase in dose, with serum TNX-4800 measurable at two days and remaining quantifiable for over 200 days in 80% of subjects at the lowest dose [5][12] Mechanism and Advantages - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, which causes 99.9% of Lyme disease cases in the U.S. [2][9] - The antibody provides passive immunity by directly supplying neutralizing antibodies, bypassing the need for a vaccine to induce the immune system [4][9] - Unlike existing vaccines that require complex immunization schedules and take over six months to provide protection, TNX-4800 offers immunity within two days with a single subcutaneous dose [3][9] Future Study Plans - The company plans to initiate a randomized, double-blind, placebo-controlled adaptive Phase 2 field study in the first half of 2027, pending FDA clearance [1][6] - The primary endpoint will be the prevention of Lyme disease at four months, with a key secondary endpoint at six months [6][11] Product Development and Background - TNX-4800 was in-licensed from UMass Chan Medical School in 2025 and is designed to maintain protective antibody levels for approximately four months [2][9] - The company expects to have GMP investigational product available for clinical testing in early 2027 [7]

Core Insights - Tonix Pharmaceuticals announced the presentation of Phase 1 data on TNX-4800, a long-acting human monoclonal antibody for the seasonal prevention of Lyme disease, at the World Vaccine Congress Washington 2026 [1][3] Group 1: TNX-4800 Overview - TNX-4800 targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease, and has shown 95% effectiveness in preventing infection in animal studies [4][6] - The antibody is designed to provide immunity within two days of administration and maintain protective antibody levels throughout the tick season, offering a pre-exposure prophylaxis without relying on the recipient's immune system [4][6] - The company expects to have GMP investigational product available for clinical testing in early 2027, with a field study anticipated to begin enrollment in the first half of 2027 [5] Group 2: TNX-801 Overview - TNX-801 is a live attenuated horsepox virus vaccine candidate aimed at preventing smallpox and mpox, expected to enter Phase 1 studies in 2027 pending FDA clearance [8] Group 3: Phase 1 Study Details - The Phase 1 study of TNX-4800 involved 44 subjects, with 41 completing the study, assessing safety, tolerability, pharmacokinetics, and immunogenicity [6] - Drug exposure increased approximately 25 times for a 20 times increase in dose, with serum TNX-4800 measurable within 24 hours and remaining quantifiable for over 200 days in 80% of volunteers at the lowest dose [6] - The mean half-life of TNX-4800 ranged from 62-69 days, with most adverse events being mild or moderate, indicating that TNX-4800 is generally safe and well tolerated [6] Group 4: Lyme Disease Context - Lyme disease is the most common vector-borne infection in the U.S., caused by Borrelia burgdorferi, with increasing incidence due to climate changes affecting tick habitats [7] - Typical symptoms include fever, headache, fatigue, and a characteristic skin rash, with untreated infections potentially spreading to joints, heart, and nervous system [7]

Core Viewpoint - Tonix Pharmaceuticals has launched TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, demonstrating rapid pain relief and a favorable benefit-risk profile in clinical studies [1][2]. Group 1: Product Overview - TONMYA (cyclobenzaprine HCl sublingual tablets) was approved by the FDA on August 15, 2025, for the treatment of fibromyalgia in adults [9]. - The formulation allows for rapid transmucosal absorption and reduces the production of a long half-life active metabolite, norcyclobenzaprine, due to bypassing first-pass hepatic metabolism [9]. - TONMYA is also being investigated for other conditions, including acute stress reaction, acute stress disorder, and major depressive disorder [9]. Group 2: Clinical Study Results - In the RESILIENT trial, TONMYA showed significant pain reduction as early as Day 2, with a statistically significant change in weekly average daily numeric rating scale (NRS) pain scores (p<0.001) [3]. - The primary endpoint was met with a least-squares mean treatment difference of -0.65, and all key secondary endpoints were statistically significant in favor of TONMYA [3]. - A pooled analysis of the RELIEF and RESILIENT studies indicated that the number needed to treat (NNT) for a clinically meaningful ≥30% pain reduction was 7, while the number needed to harm (NNH) for discontinuation due to adverse events was 26, resulting in a likelihood to be helped or harmed (LHH) of 3.7 [5]. Group 3: Safety and Tolerability - TONMYA was generally well tolerated, with a discontinuation rate due to adverse events of 6.1% compared to 3.5% for placebo [4]. - The most common treatment-emergent adverse events included oral cavity reactions, such as oral hypoesthesia (23.8%) and abnormal product taste (11.7%), which were typically mild and transient [4][6]. - Safety data were consistent with the known profile of TONMYA, with no new or unexpected safety signals reported [6]. Group 4: Market Context - Approximately 10 million adults in the U.S. suffer from fibromyalgia, with a significant unmet medical need for effective treatments [2][8]. - Physicians and patients have expressed dissatisfaction with currently marketed products, highlighting the potential market opportunity for TONMYA [8].

Core Insights - TONMYA (cyclobenzaprine HCl sublingual tablets) is the first new FDA-approved treatment for fibromyalgia in adults in over 15 years, launched commercially in the U.S. in November 2025 [1] - The formulation is designed for rapid transmucosal absorption, bypassing first-pass liver metabolism, which enhances the durability of analgesic response compared to traditional oral cyclobenzaprine [1][2] - Clinical studies indicate that TONMYA provides a durable analgesic benefit and is generally well tolerated among fibromyalgia patients [2][5] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with TONMYA as its flagship product [9] - The company is also developing other treatments, including those for major depressive disorder and acute stress disorder, leveraging its proprietary formulations [9] Product Details - TONMYA utilizes a patented sublingual formulation that enhances drug exposure during sleep while minimizing side effects associated with the active metabolite norcyclobenzaprine [8] - The product is indicated for the treatment of fibromyalgia in adults and is expected to have U.S. market exclusivity until 2034/2035 due to multiple patents [8] Clinical Study Findings - Study 1 demonstrated that the potassium phosphate dibasic formulation of TONMYA achieved a 154% relative bioavailability compared to oral immediate-release cyclobenzaprine, with a significantly shorter absorption lag [3] - Study 2 confirmed the absence of food effects on pharmacokinetic parameters and characterized the active metabolite's elimination half-life as approximately 60 hours [4] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain and other debilitating symptoms [7] - There is a noted dissatisfaction with currently marketed products for fibromyalgia, highlighting the potential market opportunity for TONMYA [7]

Core Insights - Tonix Pharmaceuticals has licensed exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist, which has shown analgesic activity in various neuropathic pain models [1][2] - The company aims to advance TNX-4900 through further pharmacokinetic, formulation, and safety studies to support IND-enabling development [4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline focused on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [5] - The company markets FDA-approved TONMYA, a non-opioid analgesic for fibromyalgia, and has additional treatments for acute migraine [5] Product Development - TNX-4900 was developed using computer-aided and AI-driven approaches, demonstrating robust analgesic efficacy and a favorable safety profile in preclinical models [2][4] - The compound binds to the human Sigma-1 receptor with a nanomolar affinity (Ki = 7.5 nM) and shows over 100-fold selectivity over the Sigma-2 receptor, with an oral bioavailability of approximately 28% [2] Research and Innovation - Foundational research into TNX-4900 represents a significant step towards developing non-opioid solutions for chronic pain, addressing the need for safer pain management options [3] - The compound has produced significant and durable reductions in pain behaviors in preclinical models without evidence of tolerance or motor impairment [4]

Group 1 - Tonix Pharmaceuticals presented promising preclinical data for its investigational mpox and smallpox vaccine candidate, TNX-801, at the World Vaccine Congress Europe 2025 [1][2] - The TNX-801 vaccine demonstrated strong immune responses, long-term protection for at least 14 months, and favorable safety across multiple animal models [2] - The company is pursuing a Phase I clinical trial in collaboration with the Kenya Medical Research Institute and is exploring microneedle patch technology for vaccine administration [2] Group 2 - Tonix Pharmaceuticals is currently unprofitable, with analysts not expecting profitability this year [2] - The company focuses on developing therapies and vaccines for central nervous system disorders, immunology, infectious diseases, and rare diseases [2] - Tonix also markets existing products for the treatment of acute migraine headaches, such as Zembrace SymTouch and Tosymra [2]

Core Insights - The RESILIENT trial data demonstrates that TNX-102 SL significantly reduces fibromyalgia pain compared to placebo, confirming previous findings from the RELIEF trial [1][2] - If approved, TNX-102 SL will be the first new drug for fibromyalgia in over 15 years, with a PDUFA target date set for August 15, 2025 [1][2] Company Overview - Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for pain management and central nervous system disorders [8] - The company has submitted a New Drug Application (NDA) for TNX-102 SL based on two statistically significant Phase 3 studies [2][8] Study Details - The RESILIENT study was a randomized, double-blind, placebo-controlled trial involving 457 adults with fibromyalgia across 33 sites in the U.S. [2][7] - Participants received TNX-102 SL in two dosage phases: 2.8 mg for two weeks followed by 5.6 mg for twelve weeks, with a primary endpoint of pain reduction assessed over fourteen weeks [2][7] Efficacy Results - TNX-102 SL achieved a least-squares mean reduction of 1.8 points on the eleven-point daily pain numeric rating scale, compared to a 1.2-point reduction for placebo, indicating high statistical significance [2][7] - Statistically significant improvements were also noted across all six prespecified key secondary endpoints, including various patient-reported outcomes [2][3] Safety Profile - TNX-102 SL was generally well tolerated, with the most common adverse events being mild and transient, such as oral tingling/numbness and a bitter aftertaste [3] - No serious drug-related adverse events or deaths were reported, highlighting a favorable risk-benefit profile [3] Fibromyalgia Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain, fatigue, and sleep disturbances [4] - Current treatment options are often met with dissatisfaction from both physicians and patients, indicating a significant unmet need in the market [4] Product Information - TNX-102 SL is a patented sublingual formulation of cyclobenzaprine hydrochloride designed for rapid absorption and reduced side effects [5][6] - The drug is also being explored for other indications, including acute stress reaction, Long COVID, and alcohol use disorder [5][8]

Core Insights - Tonix Pharmaceuticals announced that its vaccine candidate TNX-801 provides durable protection against monkeypox after a single dose [1][3] - The vaccine is well tolerated in immunocompromised animals, showing no evidence of spreading to blood or tissues even at high doses [2][3] - TNX-801 is designed to generate both humoral and cellular immunity and serves as a platform for delivering multiple protective antigens against various viral pathogens [3][4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on developing therapies for pain management and vaccines for public health challenges [6] - The company has a diverse development portfolio, including TNX-102 SL for fibromyalgia, which has a PDUFA goal date of August 15, 2025 [6] - Tonix's infectious disease portfolio includes TNX-801 for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent with a contract worth up to $34 million with the U.S. Department of Defense [6]

Core Insights - TNX-102 SL is a sublingual formulation of cyclobenzaprine aimed at treating fibromyalgia, with an FDA PDUFA goal date of August 15, 2025, potentially becoming the first new non-opioid analgesic for fibromyalgia in over 15 years [1][7] - The drug has shown statistically significant improvement in reducing fibromyalgia pain in two Phase 3 studies, demonstrating durable activity over 14 weeks [2][3] - TNX-102 SL targets sleep disturbances associated with fibromyalgia and has a favorable tolerability profile, acting as a potent antagonist at four post-synaptic receptors [3][6] Company Overview - Tonix Pharmaceuticals is a biotechnology company focused on developing therapies for pain management and CNS disorders, with TNX-102 SL as a priority product candidate for fibromyalgia [7] - The company has submitted a New Drug Application (NDA) for TNX-102 SL based on positive Phase 3 study results and has received Fast Track designation from the FDA [7] - Tonix also has a diverse development portfolio, including treatments for acute stress reactions, organ transplant rejection, and infectious diseases [7] Industry Context - Fibromyalgia affects over 10 million adults in the U.S., primarily women, and is characterized by chronic pain, non-restorative sleep, and cognitive dysfunction [4] - Current treatment options are often unsatisfactory, leading many patients to rely on chronic opioids, which carry risks of addiction and overdose [2][4] - TNX-102 SL's unique formulation aims to provide a new therapeutic option that addresses both pain and sleep disturbances without the risks associated with opioids [2][6]

Core Insights - Tonix Pharmaceuticals has appointed James "Jim" Hunter to its Board of Directors, effective June 12, 2025, to strengthen its commercial strategy and governance as it prepares for the potential launch of TNX-102 SL for fibromyalgia later this year [1][2][4] Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges, with a development portfolio centered on central nervous system (CNS) disorders [5] - The company is advancing TNX-102 SL, a product candidate for fibromyalgia management, with a New Drug Application (NDA) submitted based on two statistically significant Phase 3 studies, and a PDUFA goal date of August 15, 2025, for marketing authorization [5] Leadership and Experience - Jim Hunter has over 40 years of experience in the biopharmaceutical industry, having held leadership roles at Validus Pharmaceuticals, Relialab, and Novartis, and was instrumental in launching Tonix Medicines and entering the migraine market [1][3] - As Executive Vice President of Commercial Operations at Tonix, Hunter managed all aspects of the company's commercial efforts, including sales, marketing, and market access initiatives [2][4] Product Development and Pipeline - Tonix's immunology development portfolio includes biologics targeting organ transplant rejection, autoimmunity, and cancer, such as TNX-1500, an Fc-modified humanized monoclonal antibody [6] - The infectious disease portfolio features TNX-801, a vaccine for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent with a contract worth up to $34 million over five years with the U.S. Department of Defense [6] Commercial Strategy - Tonix Medicines, the commercial subsidiary, markets Zembrace SymTouch and Tosymra for the treatment of acute migraines, and is actively involved in pre-launch activities for TNX-102 SL, including launch strategy and market analysis [2][5][6]